AIMS: The influence of efavirenz on lopinavir pharmacokinetics was investigated using a population approach. METHODS: Forty-five HIV patients treated with lopinavir/ritonavir plus efavirenz (A) and 24 patients treated with lopinavir/ritonavir plus nucleoside/nucleotide reverse transcriptase inhibitors (B) were studied. RESULTS: A relationship (P < 0.01) was established between the elimination rate constant of lopinavir (k(10)) and treatment with efavirenz. Mean k(10) was higher in group A than in group B (0.3838 vs 0.2810 h(-1)) (P < 0.001, 95% confidence interval for difference between means 0.1004, 0.1052). CONCLUSIONS: These results suggest that lopinavir metabolism is induced by efavirenz.
AIMS: The influence of efavirenz on lopinavir pharmacokinetics was investigated using a population approach. METHODS: Forty-five HIVpatients treated with lopinavir/ritonavir plus efavirenz (A) and 24 patients treated with lopinavir/ritonavir plus nucleoside/nucleotide reverse transcriptase inhibitors (B) were studied. RESULTS: A relationship (P < 0.01) was established between the elimination rate constant of lopinavir (k(10)) and treatment with efavirenz. Mean k(10) was higher in group A than in group B (0.3838 vs 0.2810 h(-1)) (P < 0.001, 95% confidence interval for difference between means 0.1004, 0.1052). CONCLUSIONS: These results suggest that lopinavir metabolism is induced by efavirenz.
Authors: Rob E Aarnoutse; Karin J T Grintjes; Denise S C Telgt; Michael Stek; Patricia W H Hugen; Peter Reiss; Peter P Koopmans; Yechiel A Hekster; David M Burger Journal: Clin Pharmacol Ther Date: 2002-01 Impact factor: 6.875
Authors: Ann Hsu; Jeffrey Isaacson; Scott Brun; Barry Bernstein; Wayne Lam; Richard Bertz; Cheryl Foit; Karen Rynkiewicz; Bruce Richards; Martin King; Richard Rode; Dale J Kempf; G Richard Granneman; Eugene Sun Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191
Authors: V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta Journal: Clin Pharmacol Ther Date: 2012-02-08 Impact factor: 6.875
Authors: M Nikanjam; E G Chadwick; B Robbins; C Alvero; P Palumbo; R Yogev; J Pinto; R Hazra; M L Hughes; B E Heckman; E V Capparelli Journal: Clin Pharmacol Ther Date: 2011-12-21 Impact factor: 6.875
Authors: José Moltó; Manuel José Barbanoj; Cristina Miranda; Asunción Blanco; José Ramón Santos; Eugenia Negredo; Joan Costa; Pere Domingo; Bonaventura Clotet; Marta Valle Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447
Authors: Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Brian Gazzard; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Philippa Easterbrook; Sara Gibbons; Saye Khoo Journal: J Antimicrob Chemother Date: 2010-01 Impact factor: 5.790
Authors: Jennifer R King; Edward P Acosta; Ram Yogev; Andrew Wiznia; Joyce Kraimer; Bobbie Graham; Vincent Carey; Paula Britto; Patrick Jean-Philippe; John Moye; Douglas Watson Journal: Pediatr Infect Dis J Date: 2009-02 Impact factor: 2.129